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Abstract In the interaction between HIV-1 RT and tRNA Lys3 
each subunit of the heterodimer interacts with tRNA showing a 
different affinity: Kd (p66) = 23 nM, Kd (pS1) = 140 nM. Prein- 
cubation of heterodimeric RT with tRNA, at concentrations sim- 
ilar to that of the Kd value for p51, leads to an increase of the 
catalytic activity on poly(A)-oligo(dT). These results were com- 
pared to those using different tRNA analogs: oxidized tRNA, 
tRNAs lacking one, two or three nucleotides from the 3'-end, or 
ribo- and deoxyribonucleotides mimicking the anticodon loop se- 
quence. In all cases, tRNA analogs were weaker activators of 
HIV-1 liT than natural tRNA. A possible mechanism of RT 
p661p51 activation by tRNA and its analogs, mediated through 
the p5I subunit, is discussed. 
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i. Introduction 
RT plays an essential role in the life cycle of HIV-1. In virions 
HIV-1 RT has been isolated as a heterodimer consisting of 66 
and 51 kDa polypeptides [1,2]. HIV-1 RT utilizes tRNA Lys3 as 
t primer for the initiation of cDNA synthesis, as deduced from 
he retroviral genome nucleotide sequence [3]. Using different 
approaches, a complex between mammalian tRNA Lye3 and 
HIV-1 RT has been demonstrated (for a recent review see [4]). 
Fhe recognition of tRNA by HIV-1 RT occurs through the 
meraction of the anticodon and dihydrouridine loop [5,6]. The 
binding of tRNA induces ignificant structural changes in RT, 
as followed by fluorescence emission or by the accessibility of 
p66/p51, tRNA complex to chymotrypsin [7]. 
In yeast, recombinant HIV-1 RT has been isolated either as 
a heterodimer p66/p51 [8] or as a homodimer p66/p66 [9]. We 
have shown before the stimulation of RT p66/p66 by primer 
tRNA Lys3 [10]. Preincubation f RT p66/p66 with tRNA led to 
stimulation of the reaction of polymerization on poly(A)- 
oligo(dT) template-primer. Maximal activation was reached at 
equimolar amounts of tRNA and RT. tRNA did not change 
enzyme affinity to the template, primer or dNTP, but increased 
the Vma X of the reaction. In this work we show that the hereto- 
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Abbreviations: RT, Reverse transcriptase; HIV-1, Human immunodefi- 
ciency virus type 1; tRNA(-1), tRNA(-2), tRNA(-3), tRNA deriva- 
tives shortened by one, two and three nucleotides from the 3'-end. 
dimeric form of HIV-1 RT can also be activated by tRNA eys3. 
We have determined the kinetic parameters that characterize 
the activation. A model is proposed where activation of the p66 
catalytic subunit would result from the interaction of tRNA Lye3 
with the p51 subunit of RT p66/p51. 
2. Materials and methods 
Nucleotides and polynucleotides were obtained from Sigma or Phar- 
macia. Radioisotopes were purchased from Amersham or Radioisotop 
(Russia). Oligonucleotides were synthesized asin [11,12]. HIV-I RT 
p66/p51 was obtained as before [8]. tRNA was prepared according to 
[10]. Oxidation of tRNA was carried out as previously described [13]. 
tRNA(-1), tRNA(-2) and tRNA(-3) were prepared by subjecting 
tRNA to three reaction cycles of the Whitfield egradation according 
to Paulsen and Wintermeier [14] and purified using reverse phase 
chromatography [15]. Fluorescence d termination was performed as 
described in [10]. 
RT assay and activation experiments were performed as in [10]. The 
increase of RT activity was estimated from the tangent of the curves, 
time vs. polymerization. Relative values of enzyme activation were 
calculated comparing the activity of RT after and before preincubation 
with tRNA. The activation of RT during preincubation with tRNA (or 
its derivatives) is described by the linear dependence of the log of 
enzyme activity on time. The apparent rate constant of activation, kapp, 
was determined asthe slope of the semilogarithmic plot of the activa- 
tion kinetics. The activation rate constant (k) and the dissociation 
constant (Ka) for the reversible complex enzyme, tRNA (or analogs of 
tRNA) were determined according to Kitz and Wilson [16] and to 
Eisenthal and Cornish-Bowden [17]. 
3. Results and discussion 
The interaction between the p66/p51 form of RT and tRNA 
was quantitatively analyzed by fluorescence quenching. The 
stoichiometry and Kd values were obtained from the Scatchard 
plot using titration data. HIV-1 RT p66/p51 bound two mole- 
cules of tRNA with different affinities: Kdt = 23 nM; Kd2 = 140 
nM (Fig. 1). 
Since both subunits of the heterodimer can bind tRNA it was 
interesting todetermine which of the subunits has higher affin- 
ity towards its natural primer. To answer this question different 
facts were considered: (a) Cross-linking studies have shown 
that in some conditions (high trans-diaminedichloroplatinum 
concentration) tRNA is associated with both the p66- and 51- 
kDa polypeptides of heterodimer [5]. However, under condi- 
tions of limiting cross-linking agent, there would be a preferen- 
tial binding of tRNA Lys3 to the p66 subunit of the heterodimer 
(as discussed in [18]); (b) Selective tRNA binding is in part 
supported by data from Cheng et al. [19]. They showed that 
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cross-linking of template-primer and thymidine triphosphate 
substrates occurred exclusively to the p66 subunit of the heter- 
odimeric RT; (c) The affinity of p66 to a template-primer 
oligo(A)'d(pT)~ 0 is higher than that of the p51 sub- 
unit [20]; (d) The different forms of HIV-1 RT were affinity 
labeled using a 5'-modified primer, covalently linked, that was 
further elongated inthe presence of a radioactive dNTP precur- 
sor. The three forms were labeled, but with different efficien- 
cies. In the case of the heterodimer the analog preferentially 
modified the p66 subunit [21]. These results indicate that the 
active site for the reaction of polymerization resides on the p66 
subunit of the heterodimer. They support he fact that primer 
tRNA must have a higher affinity for p66 (Ko -- 23 nM) than 
for p51 (Kd = 140 nM). 
When analyzing the influence of tRNA on the activity of RT 
p66/p51, two factors should be taken into account: the compe- 
tition of tRNA and poly(A)-oligo(dT) for the catalytic subunit 
of the heterodimer and the higher affinity of tRNA for p66. 
These data could explain why tRNA cannot activate RT p66/ 
p51 when the ratio tRNA/RT is equal to one, while p66/p66 was 
stimulated at very low concentrations of tRNA. We observed 
activation of RT p66/p51 at concentrations of tRNA where, 
according to the fluorescence data, the complex p51.tRNA 
takes place. As for RT p66/p66 [10], preincubation of tRNA 
with the heterodimer p66/p51 led to the activation of the polym- 
erizing activity of RT (Fig. 2A). But the activation level was 
lower than in the case of the homodimer p66/p66 [10]. 
All activation experiments were carried out using tRNA at 
concentrations higher than RT concentration. The dilution of 
the activated enzyme (10 to 30 times) and the following incuba- 
tion for 1 h did not diminish the activation effect. These two 
conditions allowed the analysis of the activation process (at 
least during the length of time of enzyme activity determina- 
tion, 10 min) as an irreversible reaction of pseudo-first order. 
The dissociation constant (Kd) of the complex RT.tRNA was 
determined on the basis of the following reaction scheme: 
RT + tRNA RT -~ RT. tRNA (K~) 





4 8 12  
i i ! ! i 
16 20 24 28 32 
v/[tRNALys3] (nM) -1 
! 
36 
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Fig. 2. (A) Time dependence of the activation, A, of RT p66/p51 by 
tRNA Lys3. RT (4 nM) was preincubated with 20 nM (1), 50 nM (2), 100 
nM (3) or 200 nM (4) tRNA. After preincubating for different times, 
RT activity was determined in the presence of poly(A)-oligo(dT). 
(B) Data from Fig. 2A is presented as a function of In (Am~x-A) upon 
the time. The level of maximal activation (Am,x) = 300%, was taken as 
1.0. tRNA Lys3 concentration, expressed innM, was: 20 (1), 30 (2), 50 
(3), 67 (4), 100 (5), 133 (6) and 200 (7). (C) The dependence of k,pp of 
RT activation rate on the concentration f tRNA Lys3 in inverse coordi- 
nates: determination f the Kd value for the complex of the enzyme and 
tRNA. 
where k is the rate constant of the transformation f RT. tRNA 
to an activated form RT-tRNA*. 
For the treatment of the experimental data, the graphical 
plot l/kap  = l /k + Kd/k o was used, where kap v is the constant of 
enzyme activation at a fixed concentration f tRNA (xo). 
From the kinetic curves of enzyme activation, the ( , t~max-A)  
values were calculated, where Area x is the maximum level of 
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enzyme activation and A is the relative increase of RT activity 
during the time of enzyme preincubation with tRNA. The val- 
ues of kap p were estimated using the linear part of the curve, 
dependence of In (Amax-A) upon the time (Fig. 2B). The Kd 
\alue of the complex RT' tRNA (130 + 30 nM) and the value 
for the constant of maximal rate of activation (1.0 x 10 -2 min -~) 
were found from the linear dependence of kap p of enzyme acti- 
- ation upon the concentration of tRNA (Fig. 2C). 
The K d of the p51 subunit of the heterodimer valuated from 
~he fluorescence data (140 nM) was practically the same as the 
.'£d found in the activation experiments (130 nM). These results 
,uggest hat the activation of the p66 catalytic subunit in the 
~eaction of polymerization using poly(A)-oligo(dT) as tem- 
01ate-primer can be due to the interaction of tRNA Lys3 with the 
!)51 subunit of HIV-1 RT p66/p51. Thus, activation could be 
egarded as the result of the induction of conformational 
,:hanges in the interaction RT-tRNA. 
We showed earlier the important role of the 3'-end OH group 
)f the primer in its interaction with pro- and eucaryotic DNA 
~olymerases [12,15,22-25]. Here our aim was to estimate the 
:ontribution of the 3'-terminal CCA of tRNA in the interaction 
~ith HIV-1 RT p66/p51. For this purpose a periodate-oxidized 
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Fig. 3. (A) Activation of RT by the d(pN)t4-1oo p. 4 nM RT was prein- 
cubated with 0 (1), 20 (2), 50 (3), 100 (4) and 200 nM (5) d(pN)j4-1oop. 
B: Determination of the Kd value for the complex RT.d(pN)t4-1oo p 
using the method of Eisenthal and Cornish-Bowden [17]. 
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Table 1 
Parameters characterizing the interaction of HIV-1 RT p66/p51 with 
tRNA Lys3 and its derivatives determined from the activation experi- 
ments 
Activator Kd rm Maximum level of 
of RT (nM) (min) activation (%)* 
tRNA 130 + 40 21 300 
tRNA analogs: 
tRNAox 150 +_ 50 29 160 
tRNA (-1) 200 + 100 29 170 
tRNA (-2) 300 + 150 28 85 
tRNA (-3) 300 + 100 10 86 
Anticodon analogs: 
d(pN)ls-loop 160 + 70 10 38 
d(pN)j4-1oop 250 + 50 22 37 
(pCpUpU)s 250 + 50 30 50 
*Errors of the value were within 5-30%. 
tRNA without the native 3'-OH group (tRNAox) was used, as 
well as tRNA derivatives shortened by one, two or three nucle- 
otides from the 3'-end. The activation level produced by the 
tRNA analogs was lower compared to natural tRNA (Table 1). 
To evaluate the role of the anticodon loop (that has been 
shown to be important for the recognition of tRNA [5,6]) in the 
activation of RT, different oligonucleotides were used: 
(i) d(pN)~5-1oop, a hairpin-like structure with an analogous 
sequence to that of the anticodon loop of tRNALys3: d(CAG 
ACT TTT AAT CTG). The trinucleotide d(TTT) is an analog 
of the anticodon SUU, where S is thiouridine [26]. (ii) d(pN)l 4- 
loop. This oligonucleotide has the sequence d(GGG ACT CTT 
AAC CC) and contains the trinucleotide d(CTT), an analog of 
CUU, the anticodon of tRNA kysl and tRNA Lys2. (iii) 
ribo(CUU)5. 
The preincubation of RT with each oligonucleotide l d to a 
low but significant activation of the enzyme (Fig. 3A). The K d 
values were calculated from activation experiments using the 
approach described above and the method of Eisenthal and 
Cornish-Bowden [17] (Fig. 3B). Both approaches gave the same 
values (Table l). While the Kd and the half-time values of 
enzyme activation (Vl/2) for the oligonucleotides were similar to 
those for tRNA LyS3 the activation level was significantly lower. 
Summarizing the above facts the following model of interac- 
tion of tRNA with the enzyme can be proposed. At concentra- 
tions lower than Kd2, tRNA Lye3 binds to p66. At higher concen- 
trations, binding to p51 takes place inducing a conformational 
rearrangement of the heterodimer. As a consequence, the activ- 
ity of the p66 catalytical subunit is enhanced. At the same time 
the 3'-CCA-terminal sequence, as well as most probably other 
structural elements of the tRNA may be important for the 
efficiency of HIV-I RT structural changes. 
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